CervoMed (CRVO) EBIAT (2022 - 2025)
CervoMed (CRVO) has disclosed EBIAT for 9 consecutive years, with -$8.1 million as the latest value for Q4 2025.
- Quarterly EBIAT fell 20.6% to -$8.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$27.0 million through Dec 2025, down 65.53% year-over-year, with the annual reading at -$27.0 million for FY2025, 65.53% down from the prior year.
- EBIAT hit -$8.1 million in Q4 2025 for CervoMed, down from -$7.7 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $2.2 million in Q3 2023 to a low of -$8.1 million in Q4 2025.
- Historically, EBIAT has averaged -$3.5 million across 4 years, with a median of -$3.4 million in 2022.
- Biggest five-year swings in EBIAT: surged 343.63% in 2023 and later plummeted 370.55% in 2024.
- Year by year, EBIAT stood at -$1.5 million in 2022, then crashed by 54.67% to -$2.4 million in 2023, then plummeted by 183.86% to -$6.7 million in 2024, then fell by 20.6% to -$8.1 million in 2025.
- Business Quant data shows EBIAT for CRVO at -$8.1 million in Q4 2025, -$7.7 million in Q3 2025, and -$6.3 million in Q2 2025.